A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Friday 6 May 2011

Injunction lifted as Spanish escitalopram dispute edges towards full trial

Readers may have missed a recent note on the 8 March 2011 decision the Barcelona Court of Appeal to lift the preliminary ex parte injunctions sought by Lundbeck against various companies selling generic escitalopram medicaments for which they had obtained marketing approval.  This decision upheld the decision of Barcelona Commercial Court No 4 in April of last year.  At stake were Lundbeck's patent EP347.066 - ES2.986.891 and SPC 200200019, which claimed a certain manufacturing process for the active ingredient escitalopram.

The main trial in the first instance main proceedings is due to take place in July 2011.

Details of this dispute so far can be found in the source referred to below.

Source: "Appeal court lifts preliminary injunction against sale of escitalopram generics", by Sara Pelaz (Grau & Angulo), International Law Office, 3 May 2011

No comments: